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Parathyroidectomy does not prevent the renal PTH/PTHrP receptor
down-regulation in uremic rats. In a recent study we demonstrated that
the PTH/PTHrP receptor (PTH-R) mRNA was markedly down-regulated
in the remnant kidney of uremic rats with severe secondary hyperpara-
thyroidism. Among the factors potentially implicated in this down-
regulation, to date only PTH has been demonstrated to modulate PTH-R
expression. Here, we examined the effect of thyroparathyroidectomy
(TPTX) on the renal expression of PTH-R in rats with normal renal
function or with chronic renal failure (CRF) induced by 5/6 nephrectomy.
Four groups of rats were studied: control, TPTX, CRF, and CRF+TPTX.
Moderate-degree renal failure was documented by mean (± SD) creatinine
clearances (l/min/100 g body wt) of 259 40 and 212 45 in CRF and
CRF+TPTX rats, compared with 646 123 and 511 156 in control and
TPTX rats, respectively. Plasma phosphorus, calcitriol, and ionized cal-
cium were significantly lower in CRF and CRF+TPTX than in control
animals. Plasma ionized calcium and calcitriol were also lower in TPTX
than in control rats. Plasma PTH levels (pg/mi) were increased in CRF
rats (41.8 29.4), and markedly decreased in TPTX (10.1 7.8) and
CRF+TPTX (8.0 3.8) rats compared with control rats (21.7 7.5).
Northern blot analysis showed that the level of the steady-state PTH-R
mRNA in the kidney of CRF and CRF+TPTX rats was markedly
decreased compared with that of control rats, the ratios of PTH-R
mRNAIf3-actin mRNA being 0.28 0.04 and 0.27 0.03 versus 0.54
0.05, respectively. The PTH-R mRNA expression was also found de-
creased in bone tissue from two uremic animals compared with control
rats: 0.59 versus 0.78, respectively. No change was observed in the renal
PTH-R mRNA level in TPTX animals. There was also no change in the
PTH-R mRNA expression in the liver of uremic rats. The expression of
the PTHrP mRNA was comparable in the kidney of control and CRF
animals. CRF and CRF+TPTX rats showed a similarly reduced PTH-
sensitive adenylyl cyclase activity in crude renal membrane preparations,
compared with control rats. Despite the reduction of PTH-R mRNA and
PTH-sensitive adenylyl cyclase in the kidney, CRF rats with intact
parathyroid glands had lower urinary calcium excretion and higher
phosphate excretion than CRF-TPTX rats, suggesting that PTH was still
capable of controlling mineral ion metabolism through the remaining
PTH-R in the residual nephrons. In conclusion, our data demonstrate that
neither an increase in plasma PTH and phosphate nor a decrease in
plasma calcium are important in renal PTH-R down-regulation during
chronic renal failure. It is also unlikely that an increase in the locally-
produced renal PTHrP could down-regulate its own receptor.
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The mammalian kidney plays a crucial role in the homeostasis
of calcium, magnesium, and phosphate. To maintain a net bal-
ance, more than 98% of the filtered load of each ion is reabsorbed
along the nephron [1—5]. The distal parts of the nephron, namely,
the thick ascending limb of Henle's ioop, distal convoluted, and
connecting tubules are the main regulatory sites for final excretion
in the urine. These nephron segments have receptors for several
calciotropic hormones such as parathyroid hormone (PTH), cal-
citonin, and calcitriol [6—9]. Theoretically, a modification in the
expression of one or several of these receptors in the kidney could
lead to an alteration of the mineral and bone metabolism.
In a recent study we demonstrated that the renal level of the
PTH/PTH-related peptide (PTHrP) receptor (PTH-R) mRNA
and the PTH-sensitive adenylyl cyclase activity were markedly
down-regulated in the remnant kidney of uremic rats with severe
secondary hyperparathyroidism [10]. The decrease in the renal
PTH-R mRNA, with a subsequent reduction of PTH-R number,
could at least in part be responsible for the receptor desensitiza-
tion to PTH. Moreover, the renal PTH-R down-regulation in the
setting of uremia was associated with severe hypocalcemia, hyper-
phosphatemia, high plasma PTH, and low plasma calcitriol con-
centrations. These plasma abnormalities, characteristic of uremic
secondary hyperparathyroidism [11], could be partially explained
by the renal PTH-R receptor down-regulation for the following
reasons: firstly, because receptor down-regulation could directly
lead to a decrease in PTH-stimulated tubular calcium reabsorp-
tion and a decrease in phosphate excretion resulting in phosphate
retention and indirectly in hypocalcemia; secondly, because the
subsequent hyperphosphatemia could interfere with the PTH-
stimulated synthesis of 1,25 (OH)2D3 by the kidney, resulting in a
decrease in intestinal calcium absorption and hypocalcemia.
Among the factors potentially implicated in the PTH-R mRNA
down-regulation, to date only PTH has been demonstrated, in in
vitro studies, to modulate the receptor mRNA expression [12]. In
order to investigate whether circulating PTH plays an important
role in the down-regulation of its own receptor in the kidney of
uremic animals, we have assessed its renal expression in thyro-
parathyroidectomized (TPTX) uremic rats, compared with uremic
rats with intact parathyroid glands. Moreover, we have examined
the possible role of abnormal mineral ion metabolism in the renal
PTH-R down-regulation.
The results of our study show that PTH reduction to levels
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lower than normal does not prevent the PTH-R down-regulation
in the kidney of uremic rats. They also show that despite the
marked reduction in PTH-stimulated adenylyl cyclase activity and
in PTH-R mRNA expression, the residual nephrons of uremic
rats are still capable of responding to high plasma PTH concen-
trations and regulating mineral ion metabolism in a compensatory
manner, in keeping with the "trade-off" hypothesis [13, 14].
Methods
Animals and surgical procedures
Thirty male, 12- to 14-week-old Wistar AF rats (IFFA CREDO,
Lyon, France) weighing 250 to 300 g were fed ad libitum with a
standard diet containing 0.9% P, 1.2% Ca, 0.2% Mg, 25% protein,
and 2,000 UI/kg vitamin D3. Animals were allowed free access to
food and deionized water.
They were divided in four groups. A first group of seven rats
underwent a sham operation (renal decapsulation) and served as
control animals. A second group of six rats had 5/6 nephrectomy
according to a standard two-step operation method [15] leading to
chronic renal failure (CRF). A third group of eight rats underwent
total thyroparathyroidectomy and 5/6 nephrectomy (CRF+TPTX).
TPTX was performed 10 days before the 5/6 nephrectomy. Lastly,
a fourth group of nine rats with normal renal function underwent
TPTX alone (TPTX). TPTX in these animals was also performed
10 days before renal sham operation.
Four weeks after the second renal surgery, all animals were
placed in metabolic cages for a three-day adaptation period
followed by a three-day period of renal function assessment.
Blood and urine biochemistry
The fifth week after renal surgery, all the animals were anes-
thetized by injection of pentobarbital i.p. before sacrifice and a
blood sample was obtained by aortic puncture. An aliquot of
heparinized blood was used for ionized calcium determination
(ICA1 Ionized Calcium Analyzer, Radiometer, Copenhagen,
Denmark). The remaining blood was centrifuged at 3,000 g for 20
minutes. Plasma was stored at —50°C until assays were performed.
Plasma total calcium, phosphorus, magnesium, total protein con-
centration, urea and creatinine were determined by standard
laboratory methods performed on a multiparametric analyzer
(Hitachi 717 analyzer, Boehringer Mannheim, Germany). For the
determination of calcium, phosphate, magnesium, creatinine, and
urea concentrations in urine, samples were diluted 1:5 (vol/vol) in
sterile bi-distilled water.
Plasma rat immunoreactive parathyroid hormone (riPTH) was
measured with a rat PTH (IRMA) kit (Immutopics, Inc., CA,
USA) [10, 16] recognizing the N-terminal portion of the hormone.
Plasma calcitriol was measured by radioreceptor assay (Nichols
Institute, San Juan Capistrano, CA, USA) using calf thymus
receptor according to the method of Hollis [17].
Preparation of renal membranes
The cortex of kidneys from control, TPTX, CRF, and
CRF+TPTX rats was dissected and renal membranes were
prepared by a modification of the procedure described by Marx,
Fedak and Aurbach [18]. After homogenization in a 30% (vol/vol)
buffer solution containing 0.25 M sucrose, 10 mM Tris and 1 m
Na2EDTA, p1-I 7.5, the tissue was diluted 1:1 with buffer solution
and centrifuged at 4°C in a Sorvall ultracentrifuge. When the
rotor speed reached 4,500 rpm, centrifugation was stopped and
the supernatant was collected. After a second identical centrifu-
gation the supernatant was centrifuged at 4,500 rpm for 15
minutes. The supernatant was discarded and the upper portion of
the resulting "double-layered" pellet was resuspended in 3 vol-
umes of a buffer solution containing 10 mlvi Tris, 1 mM Na2EDTA,
pH 7.5 and stored at —80°C until used for the determination of
protein concentration and adenylyl cyclase activity. Protein con-
tent was measured using the bicinchoninic acid (BCA) protein
assay (Pierce, Rockford, Illinois, USA), a modification of the
original Lowry method [19].
Adenylyl cyclase assay and cAMP measurement
The adenylyl cyclase assay was a modification of the procedure
described by Carnes, Anast and Forte [20]. The reaction mixture
contained: renal membrane preparation containing 75 jig of
protein, 0.1% bovine serum albumin, 50 mrvi Tris-HC1 (pH 7.5),
1.7 mtvi MgCl2, 1.2 mivi ATP, 7 mivi phosphocreatine, 1 m
3-isobutyl-1-methylxanthine (IBMX), and 1.08 units of creatine
kinase. This preparation was incubated for 30 minutes at 37°C
with vehicle (acetic acid 10 mM), 10 mrvi NaP, 1 mrvi forskolin, or
1 jIM rat [Nle8'21,Tyr34] PTH (1-34) from Bachem (CA, USA).
The reaction was stopped by adding 500 1d of 95% ethanol and
the denatured proteins were removed by centrifugation five
minutes at 3,000 rpm. The supernatant was lyophilized and
resuspended in 1 ml of 50 m Na acetate pH 6.2. The amount of
cAMP generated was measured by a radioimmunoassay method.
The 125I-labeled cAMP was purchased from ERIA Diagnostics
Pasteur, France, and we used a rabbit polyclonal antibody raised
against cAMP which was offered by Dr. P. Ronco (Paris, France).
RNA preparation and Northern blot hybridization
Total RNA from homogenized renal, liver, and femoral head
tissues was prepared using the acid-guanidinium-isothiocyanate-
phenol-chloroform extraction method [21]. Poly (A) RNA was
selected by oligo (dT) chromatography. RNA preparations were
denatured and separated by electrophoresis (1% agarose/2.2 M
formaldehyde gel), transferred to a nitrocellulose membrane
(Schleicher & Schuell, Keene, NH, USA), and baked (2 hr, 80°C).
The filters were hybridized with a 1.8 kb, BamHI-NotI cDNA
fragment corresponding to most of the rat PTH/PTHrP receptor
eDNA's coding region [22]. The probe was 32P-labeled using the
random-priming method to a specific activity of 1 x I o° cpm/tg.
All filters were prehybridized for three to four hours at 42°C with
a solution containing 50% of formamide, 6.6>< standard saline
citrate (SSC), 0.1% SDS, 5>< Denhardt's solution, 200 pg/mI of
salmon sperm DNA and 0.01 M EDTA. The labeled probe was
then added to the prehybridization solution (1 >< 106 cpm/ml) and
the filters were incubated overnight (16 to 18 hr) at 42°C. They
were then washed twice, 30 minutes at 42°C with 300 ml of 1><
SSC plus 0.1% SDS, and 30 minutes at 65°C with the same
solution. The filters were exposed to an autoradiographic film with
an intensifying screen for seven days at —80°C, After hybridiza-
tion with the PTH/PTHrP receptor probe and exposure, the filters
were washed for 30 mm at 95°C in 0.01% SDS, and rehybridized
with either a 450 bp-Hinf I fragment of a human f3-actin eDNA
[23] which was also 32P-labeled by random-priming or with a 30
base pairs oligomer (5' GGG TGG AGG CCG CCG CGA GTG
CAG ATC YI'G 3') complementary to the 28S ribosomal RNA
which was 32P end-labeled using the bacteriophage polynucleotide
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Table 1. Plasma biochemistry
Control
(N=7)
TPTX
(N=9)
CRF
(N=6)
CRF+TPTX
(N=8)
Total proteins g/iiter 62.1 1.2 67.7 2.6° 55.3 4.7 61.5 3.4
Urea mM 6.7 1.2 7.5 1.2 22.7 1.2" 25.0 7.7"
Creatinine p.M 35 6 55 4° 115 6b 129 37"
Total calcium miv 2.69 0.11 1.85 0.45° 2.58 0.19 2.53 0.18
Ionized calcium mvi 1.30 0.09 1.01 0.16° 1.24 0.07 1.10 0.08°
Phosphate mM 2.82 0.14° 3.37 0.48a 2.23 0.26 2.03 0.24
Magnesium m 0.75 0.05 0.62 0.05 0.73 0.05 0.80 0.05
riPTH-(1-34)pg/mi 21.7 7.5° 10.1 7.8 41.8 29.4° 8.0 3.8
Calcitriol pg/mi 73.7 12.6° 19.3 8.2 22.1 13.8 4.4 2.3a
Abbreviations are: riPTH-(1-34), rat immunoreactive parathyroid hor-
mone fragment (1-34). Results are expressed as mean SD.
a P < 0.01 compared to the three other groups
h p < 0.001 compared to control and TPTX groups
cp < 0.02 compared to CRF
kinase [24]. The abundance of PTH-R, /3-actin, and 28S RNAs
was quantified by densitometric analysis (Scan Analysis, Biosoft,
UK). The PTH-R mRNA expression was normalized to the
densitometric values obtained for the 13-actin probe and for the
28S ribosomal RNA. Results are expressed as the ratio PTH-R/
/3-actin mRNA, and PTH-R/28S ribosomal RNA.
Slot blot hybridization
Total RNA prepared from the kidney of control and CRF
animals was loaded on each slot, denatured and fixed on a
nitrocellulose membrane as described by Kafatos, Jones and
Efstratiadis [25]. The filter was prehybridized for three to four
hours as described above and then hybridized with a 1,087 bp
fragment of the rat PTHrP cDNA provided by Dr. A.C. Karaplis
(McGill University, Canada) [26], and with the previously de-
scribed 28S ribosomal RNA probes [24], respectively. The auto-
radiograph was developed after a 10-day exposure with an inten-
sifying screen at —80°C for the PTHrP mRNA and only 15
minutes for the 28S ribosomal RNA. The PTHrP mRNA expres-
sion was normalized to the densitometric values obtained for the
28S ribosomal RNA. Results are expressed as the ratio PTHrP/
28S ribosomal RNA.
Statistical analysis
Results have been expressed as means SD and statistical
significance determined by the unpaired Student's t-test or
ANOVA test, as appropriate. P values less than 0.05 were
considered significant.
Results
Plasma biochemistry
Table 1 shows the results of plasma biochemistry. Mean (± SD)
plasma creatinine levels were higher in CRF and CRF+TPTX
than in control and TPTX rats even though their body weight
remained comparable. Mean blood ionized calcium was signifi-
cantly lower in TPTX, CRF, and CRF+TPTX than in control
animals. At this degree of renal insufficiency, plasma phosphorus
was lower in CRF and CRF+TPTX than in control rats. TPTX
animals had the highest plasma phosphorus levels. There was no
significant difference in total plasma magnesium in the four
groups. Plasma riPTH levels were significantly higher in CRF than
in rats with normal renal function and significantly lower in TPTX
Table 2. Urine biochemistry
CRF+
Control TPTX CRF TPTX
(N = 7) (N = 9) (N = 6) (N = 8)
Urine volume 5 1 5 2 14 3b 10 3'
ml/24 hr/i00 g body wt
Creatinine 37.3 7.4 40.7 14.8 42.6 6.2 37.8 5.7
p.moi/24 hr/100 g body wt
Urea 4.2 1.1 4.6 1.7 5.0 2.1 5.0 1.4
mmoi/24 hr/i 00 g body wt
Calcium 27 10 23 18 29 12 63 26°
p.mol/24 hr/iOO g body wt
Phosphate 20 10 10 7 100 50° 40 ioa
p.mol/24 hr/i00 g body wt
Magnesium 3 2° 21 13° 41 12 55 18
jnnoi/24 hr/iOO g body wt
Results are expressed as mean sii
a p < 0.01, compared to three groups
bp < 0.001, compared to control and TPTX groups
Table 3. Calculations
CRF+
Control TPTX CRF TPTX(N 7) (N = 9) (N = 6) (N = 8)
Creatinine 646 123° 511 156° 259 40 212 45
p.1/min/i00 g body wt
FE calcium 1.0 0.3 1.7 0.9 3.1 1.1° 8.1 2.3°
Cra/Cc, X 100
FE phosphate 0.8 o.sa 0.2 0.1 13.8 7.2a 6.9 2.2a
CPO4/CC, x 100
FE magnesium 0.3 0.2° 6.9 2.8° 16.3 11.2 21.4 7.1
CM5/CC.)< 100
Abbreviations are: FE, fractional excretion; Ce,,, calcium clearance;
Ce,, creatinine clearance; Cr04, phosphate clearance; CM5, magnesium
clearence.
a P < 0.01, compared to three groups. Results are expressed as mean
SD.
and CRF+TPTX rats than in rats with intact parathyroid glands.
Mean plasma calcitriol concentration was significantly lower in
CRF, TPTX, and CRF+TPTX than in control rats. Even though
there was no significant difference in the calculated protein intake
among the four groups, total plasma protein concentration was
higher in TPTX rats than in other groups.
Urine biochemistry and calculations
Twenty-four-hour urine volume was two to three times higher
in CRF and CRF+TPTX, than in control and TPTX animals,
respectively (Table 2). Daily urinary excretion of creatinine and
urea were comparable in four groups (Table 2). Mean creatinine
clearances were significantly lower in CRF and CRF+TPTX rats
than in control and TPTX rats, respectively (Table 3). Total and
fractional urinary calcium excretion were significantly higher in
CRF+TPTX rats than in control, TPTX, and CRF rats (Tables 2,
3 and Fig. 1). Total and fractional urinary phosphate excretion
were significantly higher in CRF rats than in control, TPTX, and
CRF+TPTX rats (Tables 2, 3 and Fig. 1). Total and fractional
urinary magnesium excretion were significantly higher in
CRF+TPTX rats than in control, TPTX, and CRF rats (Tables 2,
3 and Fig. 1).
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Fig. 1. The fractional excretion (x 100) of calcium (LII), phosphate (0),
and magnesium (A) in the four groups of rats.
Adenylyl cyclase activity
Basal adenylyl cyclase activities in crude renal membrane
preparations were not significantly different in the four groups of
animals (Table 4). However, the adenylyl cyclase activity was
reduced in rats with CRF and CRF+TPTX as compared with
normal and TPTX rats after stimulation by NaF, forskolin, and
PTH, respectively. TPTX rats had a significantly higher PTH-
stimulated adenylyl cyclase activity than the other three groups of
animals (Table 4).
PTH-R mR/VA
The level of the steady-state PTH-R mRNA in the kidney of
CRF and CRF+TPTX rats was markedly decreased compared
with that of control rats, the ratio PTH-R mRNA//3-actin mRNA
being 0.28 0.04, and 0.27 0.03 versus 0.54 0.05, respectively,
and the ratio PTH-R mRNA/28S being 0.30 0.05 and 0.33
0.09 versus 0.57 0.05, respectively (Fig. 3). No change was
observed in the renal level of PTH-R mRNA in TPTX animals
(Fig. 2). The ratio PTH-R mRNA//3-actin mRNA in control rats
was 0.90 0.04 and in TPTX rats 0.90 0.05 (Fig. 2). There was
a significant reduction in the PTH-R mRNA expression in the
bone tissue of two uremic rats: the ratio PTH-R mRNA/28S was
0.78 in control animals versus 0.59 in CRF animals (Fig. 4). This
PTH-R down-regulation seems to be specific for the remnant
kidney and for the bone since no significant change was observed
in the PTH-R mRNA expression in other organs including the
heart (data not shown) and the liver. In the liver the ratio PTH-R
mRNA/f3-actin mRNA was 3.06 in a control rats versus 2.99 in
uremic rats (Fig. 5).
Slot blot hybridization
Figure 6 shows slot blot analysis of renal tissue from control
(1 to 4) and uremie animals (CRF, 5 to 8). No significant
difference was found in the renal expression of PTHrP mRNA
between control and uremic rats. The ratio PTHrP mRNA/28S
ribosomal RNA was 0.50 0.06 versus 0.41 0.02 in control and
CRF rats, respectively (Fig. 6).
Discussion
The present study demonstrates that the reduction of plasma
PTH concentration after TPTX to levels near zero did not prevent
Control
(N=7)
TPTX
(N=6)
CRF
(N=6)
CRF+TPTX
(N=6)
Absolute values
pmol of cAMP!
30 mm at 370
C/pg of protein
Basal 18.1 2.0 13.2 3.0 18.3 4.6 14.9 4.4
NaF 192.0 56.7 163.5 53.3 107.8 11.3° 111.7 8.7a
Forskolin 139.5 31.3 113.7 30.4 90.4 26.4° 70.6 12.6°
PTH 81.7 9.0 98.5 7.9 61.7 8.6° 48.4 22.2a
Relative values
Basal 1 1 1 1
NaF 10.6 3.1 9.2 6.5 5.8 6.2° 7.1 1.1°
Forskolin 7.7 1.7 8.6 2.3 4.9 1.4° 4.7 0.8°
PTH 4.2 0.4 7.4 0.6 3.6 1.0° 3.2 1.4
Seventy-five micrograms of protein from the renal cortex membrane
preparation was incubated for 30 mm at 37°C with vehicle (acetic acid 10
mu), 10 mM NaF, 1 msi forskolin, or 1 jiM (1-34) rat PTH, in presence of
1 mM IBMX. Abbreviations are: CRF, chronic renal failure; NaF, sodium
fluoride; TPTX, thyroparathyroideetomy. Values are expressed as means
SD.
aP < 0.05, compared to control and TPTX groups.
the decrease in the renal PTH-R expression induced by chronic
renal failure. It also shows that despite reduced PTH-R expres-
sion, uremic rats with intact parathyroid glands and secondary
hyperparathyroidism had lower urinary calcium and magnesium
excretion and higher phosphate excretion than uremic TPTX
animals. This suggests that at this stage of moderate-degree
uremia PTH still exerts a powerful action regulating mineral ion
metabolism through the remaining PTH-R in the kidney.
Previous in vitro studies [12, 27—291 and in vivo studies in rats
with normal renal function [30, 31] have illustrated that excess of
endogenous plasma PTH or pre-treatment with PTH reduced the
PTH-R number, as assessed by radioreceptor assays, and partially
desensitized the PTH-stimulated adenylyl cyclase activity and the
calcium messenger system [29]. However, it is still ill understood
whether the desensitization to PTH is due to decreased PTH-R
number and/or to post-receptor events, such as receptor internal-
ization, sequestration, degradation, and phosphorylntion or un-
coupling from transducing G proteins. Neither is it known
whether the reduced PTH-R number in these studies was the
consequence of pre- or post-transcriptional PTH-R gene regula-
tion. There are several observations supporting a negative regu-
latory effect of PTH on the PTH-R mRNA. First, when cultured
rat (ROS 17/2.8) or human osteoblastic-like cells (SaOS-2) were
treated with PTH, a moderate reduction in the level of the
steady-state PTH-R mRNA has been observed after two days of
treatment [12, 32]. However, its expression tended to normalize
toward the sixth day, despite the continuous treatment with PTH.
Second, PTH blocked the increase in PTH-R mRNA induced by
dexamethasone in ROS 17/2.8 cells [12]. Third, we have observed
only a transient decrease in the renal PTH-R mRNA in an in vivo
model of phosphate-induced acute hypocalcemia and increased
plasma PTH levels (personal unpublished results).
In spite of all this evidence, the results obtained in the present
study indicate that the renal PTH-R down-regulation during
chronic renal failure requires other factors than solely high
plasma PTH levels. This is in accord with the recent observation
0
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Table 4. Adenylyl eyelase activity expressed as absolute values (pmol of
cAMP/30 mm at 37°C/jig of protein) and values relative to the basal
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Group of animals
that the reduction of increased plasma PTH to normal levels did
not improve the blunted calcemic response to PTH in azotemic
animals [33]. Our results also rule out a direct role of plasma
calcium or magnesium concentrations in the PTH-R down-regu-
lation. Plasma levels of these ions in uremic rats were not
significantly different from those of control animals. It is also
unlikely that plasma phosphate concentration plays a role in the
receptor down-regulation. CRF rats of the present study had an
even lower plasma phosphate level than control rats, in contrast to
the marked diet-induced hyperphosphatemia in the CRF rats of
our previous study [10]. Furthermore, the high plasma phosphate
levels observed in the TPTX group with intact kidneys and no
receptor down-regulation strengthen our conclusion that hyper-
phosphatemia has no influence on the renal PTH-R mRNA.
Even though no direct evidence is available, one could hypoth-
esize that plasma calcitriol concentration is an important factor
regulating the PTH-R expression in the kidney of uremic animals.
A recent in vitro study in mouse renal distal tubular cells has
shown that 1,25 (OH)2D3 up-regulated the PTFI-R mRNA [341.
Moreover, it has been demonstrated that the impaired calcemic
response to PTH in humans and animals could be reversed by the
administration of 1,25 (OH)2D3 [35]. Nevertheless, it should be
noted that the level of PTH-R mRNA was normal in the kidney of
TPTX rats which had a decrease in plasma calcitriol level similar
to that of CRF rats, compared with control animals. Therefore,
whether the correction of the diminished plasma 1,25 (OH)2D3
concentration in uremic animals has a positive effect on renal
PTH-R expression remains to be determined. At this degree of
renal failure and despite the high PTH levels, CRF rats could not
maintain normal plasma calcitriol concentrations, probably be-
cause of either the reduced renal mass, renal PTH-R down-
Fig. 2. The upper panel shows Northern blot
analysis of kidney tissue from 3 representative
control and 3 thyroparathyroidectomized (TPTX)
rats. Twenty micrograms of total RNA were
loaded in each lane, transferred to a
nitrocellulose membrane and hybridized with
the rat PTH/PTHrP receptor probe. The
autoradiograph was developed after a 7-day
exposure with an intensifying screen at —80°C.
The lower panel shows the results of the
hybridization of the same filter with the J3-actin
probe after a 2-day exposure. The bar graph
shows the densitometric values obtained for the
PTH!PTHrP receptor and for J3-actin
hybridizations, expressed as the ratio
PTH/PTHrP receptor! /3-actin in the three
control (LI) and TPTX (i2) rats.
regulation, or uremic substances [36, 37] inhibiting PTH-stimu-
lated 1ev hydroxylation of 25 OH D3. Thus, it is possible that the
PTH-R down-regulation in the kidney contributes to calcitriol
deficiency and initiates secondary hyperparathyroidism even in
the absence of hypocalcemia or hyperphosphatemia.
Local factors could also be involved in the renal receptor
down-regulation. A recent observation in rats pointed out that
acute renal ischemia resulted in increased local secretion of
PTHrP and decreased levels of PTH-R mRNA in the kidney [38].
It has also been observed that PTHrP reduces the PTH-R number
and desensitizes the PTH-stimulated adenylyl cyclase activity in
ROS 17/2.8 cells [28]. Therefore, it could be possible that high
concentrations of locally-produced PTHrP could favor the inter-
action with the PTH-R and induce its down-regulation. However,
our findings demonstrating no change in the renal PTHrP mRNA
expression in uremic rats did not support this hypothesis. Several
cytokines have also been demonstrated to modulate the PTH-R
number. For instance, TNFa and interleukin-1 down-regulated
the PTH-R in osteoblast-like cells [39, 401. Thus, it is possible that
high circulating levels of cytokines, which have previously been
demonstrated to occur in chronic renal failure [41], or locally
produced cytokines contribute to the PTH-R down-regulation.
Cytokine-induced PTHrP production may also be implicated in
receptor down-regulation [42, 43], In addition, several peptides
such as angiotensin II are capable of diminishing the PTH-R
mRNA level in cultured smooth muscle cells [44, 5I. High
concentration of angiotensin II has been found in glomerular
filtrate, star vessel plasma and the lumen of the proximal tubule of
uremic animals [46, 47]. Local overproduction or deficiency of
other growth factors could also be theoretically involved.
In the present study we also confirm our previous observation
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Fig. 3. Northern blot analysis of kidney tissue from 6 pairs of control, uremic (CRF), and CRF+ TPTXanimals. Twenty micrograms of total RNA were
loaded in each lane, transferred to a nitrocellulose membrane and hybridized with the rat PTH/PTHrP receptor, /3-actin, and 28S ribosomal RNA
probes, respectively. The corresponding bar graphs show the densitometric values obtained for the PTH/PTHrP receptor, /3-actin, and 28S ribosomal
RNA hybridizations, expressed as the ratio PTFI/PTHrP receptor/13-actin and PTH/PTHrP receptor/28S ribosomal RNA in the control (•), CRF (LI),
and CRF+TPTX (tilL) rats.
demonstrating a decreased PTH-stimulated adenylyl cyclase ac-
tivity in renal membranes of azotemic rats [10]. However, we did
not observe any difference in the basal activity between normal,
uremic, and TPTX animals. This may be explained either by the
moderate degree of chronic renal failure or by the lower plasma
concentrations of phosphorus and PTH in the present animals.
Although the renal PTH-R mRNA was normally expressed,
PTH-stimulated adenylyl cyclase activity was significantly higher
in TPTX animals compared with normal and azotemic rats. This
could be due to a phenomenon of hypersensitization following
hormone depletion as described for other hormonal systems [48].
Concerning the effects of the renal PTH-R down-regulation on
mineral ion metabolism and its possible role in the development
of secondary hyperparathyroidism, we observed that even though
the renal PTH-R in CRF rats with intact PTH glands was
down-regulated, these animals were normocalcemic and capable
of reabsorbing the filtered urinary calcium and magnesium to a
much greater extent than CRF+TPTX rats. The hypocalcemia
and the marked increase in absolute and fractional urinary
calcium and magnesium excretion found in CRF+TPTX animals
suggest that in rats with moderate chronic renal failure having
intact PTH glands the remaining renal PTH-R still responded to
high plasma PTH levels activating para- or intracellular mediators
of tubular calcium and magnesium reabsorption. In contrast, the
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Fig. 4. Northern blot analysis of bone tissue from control (lane 1 and 2) and
from uremic (lane 3 and 4). Twenty micrograms of total RNA, extracted
from the femoral head, were loaded in each lane, transferred to a
nitrocellulose membrane and hybridized with the rat PTHIPTHrP recep-
tor, and with the 28S ribosomal RNA probes, respectively.
tubular reabsorption of these two ions, which was already altered
due to CRF, was further diminished by TPTX. Interestingly,
plasma magnesium levels of CRF+TPTX rats did not differ
significantly from those of controls and CRF rats, while their
absolute urinary magnesium excretion was twenty times higher,
and their fractional excretion hundred times higher than that of
control rats. This may indicate that urinary magnesium excretion
is even more tightly controlled by PTH and/or vitamin D than
urinary calcium excretion. The normal plasma magnesium con-
centration in the state of PTH and vitamin D deficiency suggests
that other mechanisms are responsible for maintaining its plasma
concentration within rather narrow limits.
As discussed above, hypophosphatemia was found in this model
of moderate CRF in spite of PTH-R down-regulation in the
kidney. It is generally accepted that the absence of hyperphos-
phatemia in early renal failure does not necessarily indicate an
altered phosphate metabolism. Normal or even low plasma phos-
phorus levels are often found at this degree of renal failure,
probably due to high plasma PTH concentrations [49] or to
uremic phosphaturic factors [4, 50].The presence of such uremic
phosphaturic factors may be suggested by the observation that the
fractional excretion of phosphate remained high in CRF+TPTX
rats. Taken together, these results make the hypothesis difficult to
accept that hyperphosphatemiaper se is a major factor in the early
development of uremic secondary hyperparathyroidism.
The finding of a down-regulation of the PTH-R mRNA in bone
tissue and not in the liver and in the heart suggests that the
PTH-R expression is regulated in a cell specific manner regardless
of the uremic state. Accordingly, the in vivo tissue-specific regu-
lation of the PTH-R observed in the present study supports our
prior in vitro observation showing that glucocorticoids up-regu-
lated the PTH-R in osteoblastic cells (ROS 17/2.8) whereas they
down-regulated it in renal cells (OK) [12]. Both, the reduced
PTH-R mRNA in the kidney and in bone may be the mechanisms
responsible for the blunted calcemic response to PTH in azotemic
animals.
In conclusion, our data demonstrate that neither elevated
18 S 13-actinmRNA
Ratio PTH/PTHrP 3.06 2.97 3.01
receptor/3-actin
Fig. 5. Northern blot analysis of liver tissue from control (lane 1), uremic
(CRF, lane 2), and CRF+thyroparathyroidectomized (CRF-I- TPTX, lane 3)
animals. Five micrograms of poly (A) RNA were loaded in each lane,
transferred to a nitrocellulose membrane and hybridized with the rat
PTI-I/PTHrP receptor, and with 13-actin probes, respectively.
plasma PTH and phosphate nor decreased plasma calcium are
important factors in renal PTH-R down-regulation during chronic
renal failure. It is also unlikely that an increase in the locally-
produced renal PTHrP could down-regulate its own receptor.
They also demonstrate that despite this down-regulation, the
kidney of uremic rats is still capable of responding to high plasma
PTH concentrations in a compensatory manner. There is no
hyperphosphatemia secondary to renal PTH-R down-regulation
in the initial stage of chronic renal failure. Therefore, an extra-
cellular phosphate retention cannot be considered as a major
factor in the early development of secondary hyperparathyroid-
ism.
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